I am no expert Shellb, but I see PTX 200 as a totally different enterty to the AML CarT drug.
PTX 200 didnt work very well as a mono therapy. but did work well in combination. So maybe future arming of CarT tech is viable, but I dont know.
The PTX CarT for AML targets CD33. This is one of the most expressed surfaced antigens on the AML cancer cell. It also targets CLL 1. This is found on the cancer stem cells, and believed to be the cause of relapse.
So to me, thats a totally different approach to AML treatment than PTX 200. Now if these two drugs could work in combination twin barrel like. I dont know.
Ann: PTX-200 AML Trial Progresses to Higher Dose, page-39
Add PTX (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
3.9¢ |
Change
-0.001(2.50%) |
Mkt cap ! $31.40M | |||
| Open | High | Low | Value | Volume |
| 4.1¢ | 4.1¢ | 3.9¢ | $72.73K | 1.802M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 5 | 436541 | 3.9¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 4.1¢ | 560576 | 1 |
View Market Depth
| Last trade - 15.59pm 15/11/2024 (20 minute delay) ? |
| PTX (ASX) Chart |